R 348 fails Phase II trial for Dry Eye Disease - Rigel
Rigel Pharmaceuticals, Inc. announced that R 348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase II clinical study in patients with Dry Eye Disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R 348 for this indication, but is continuing its Phase II study of dry eye in patients with graft versus host disease (GvHD).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins